Arcus Biosciences Return on Investment 2017-2022 | RCUS
Current and historical return on investment (ROI) values for Arcus Biosciences (RCUS) over the last 10 years.
| Arcus Biosciences ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2022-12-31 |
$-0.28B |
|
inf% |
| 2022-09-30 |
$0.08B |
|
inf% |
| 2022-06-30 |
$0.07B |
|
inf% |
| 2022-03-31 |
$0.06B |
|
inf% |
| 2021-12-31 |
$0.05B |
|
inf% |
| 2021-09-30 |
$-0.28B |
|
inf% |
| 2021-06-30 |
$-0.20B |
|
inf% |
| 2021-03-31 |
$-0.17B |
|
inf% |
| 2020-12-31 |
$-0.12B |
|
inf% |
| 2020-09-30 |
$-0.09B |
|
inf% |
| 2020-06-30 |
$-0.11B |
|
inf% |
| 2020-03-31 |
$-0.10B |
|
inf% |
| 2019-12-31 |
$-0.09B |
|
inf% |
| 2019-09-30 |
$-0.08B |
|
inf% |
| 2019-06-30 |
$-0.07B |
|
inf% |
| 2019-03-31 |
$-0.06B |
|
inf% |
| 2018-12-31 |
$-0.05B |
|
inf% |
| 2018-09-30 |
$-0.05B |
|
inf% |
| 2018-06-30 |
$-0.07B |
|
inf% |
| 2018-03-31 |
$-0.06B |
|
inf% |
| 2017-12-31 |
$-0.05B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.194B |
$0.112B |
|
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
|
